Kringle Pharma, Inc. (TYO:4884)
Japan · Delayed Price · Currency is JPY 441.00
-15.00 (-3.29%)
Aug 27, 2026, 2:43 PM JST
Kringle Pharma Revenue
Kringle Pharma had revenue of 287.15M JPY in the quarter ending June 30, 2026, with 1,498.40% growth. This brings the company's revenue in the last twelve months to 342.21M, up 372.42% year-over-year. In the fiscal year ending September 30, 2025, Kringle Pharma had annual revenue of 72.00M, down -10.00%.
Revenue (ttm)
342.21M
Revenue Growth
+372.42%
P/S Ratio
11.17
Revenue / Employee
n/a
Employees
17
Market Cap
3.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 72.00M | -8.00M | -10.00% |
| Sep 30, 2024 | 80.00M | 11.00M | 15.94% |
| Sep 30, 2023 | 69.00M | -322.00M | -82.35% |
| Sep 30, 2022 | 391.00M | 102.00M | 35.29% |
| Sep 30, 2021 | 289.00M | -178.00M | -38.12% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Human Metabolome Technologies | 1.42B |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| Veritas In Silico | 84.42M |
| Ribomic | 7.50M |
| FunPep Company | 1.00M |